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Abstract 
Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of 
members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid cell leukemia-1 
(MCL-1) acts as a master regulator of apoptosis in various human malignancies. Irrespective of its unfavorable struc-
ture profile, independent research efforts recently led to the generation of highly potent MCL-1 inhibitors that are cur-
rently evaluated in clinical trials. This offers new perspectives to target a so far undruggable cancer cell dependency. 
However, a detailed understanding about the tumor and tissue type specific implications of MCL-1 are a prerequisite 
for the optimal (i.e., precision medicine guided) use of this novel drug class. In this review, we summarize the major 
functions of MCL-1 with a special focus on cancer, provide insights into its different roles in solid vs. hematological 
tumors and give an update about the (pre)clinical development program of state-of-the-art MCL-1 targeting com-
pounds. We aim to raise the awareness about the heterogeneous role of MCL-1 as drug target between, but also 
within tumor entities and to highlight the importance of rationale treatment decisions on a case by case basis.
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Introduction
The intrinsic apoptosis pathway represents the most 
prominent cell death signaling cascade and is primar-
ily controlled by the BCL-2 family of proteins. This can 
be split into pro-survival/anti-apoptotic (BCL-2, BCL-
xL, MCL-1, BCL-W, BFL1), effector (BAK, BAX, BOK), 
BH3-only activator (BIM, BID, PUMA) and sensitizer 
(NOXA, BAD, BMF, BIK, Hrk) proteins [1]. The deci-
sion between cellular survival and death depends on the 
precise balance of these anti- and pro-apoptotic pro-
teins. Under homeostasis, anti-apoptotic proteins bind to 
and sequester both BH3-only activator as well as effec-
tor molecules thereby ensuring cellular survival. In the 
presence of a cell death stimuli (e.g., radiation, chemo-
therapy), however, transcriptional upregulation as well as 
prost-translational modifications of BH3-only activator 
and/or sensitizer proteins initiate the intrinsic apopto-
sis pathway. BH3-only activator and sensitizer proteins 
directly bind to anti-apoptotic BCL-2 family members 
with high-affinity which mediates the release of seques-
tered effector molecules (BAK and BAX). Moreover, free 
BH3-only activator proteins directly bind to and activate 
BAK/BAX, which leads to BAK/BAX homo-oligomeri-
zation, mitochondrial outer membrane permeabilization 
(MOMP), release of cytochrome c into the cytosol and 
finally caspase activation [1].
In healthy cells, the balance between death and 
pro-survival signals is a tightly regulated process that 
depends on tissue location and age [1–3]. In adults, 
non-hematopoietic organs (e.g., brain, heart and kid-
neys) are characterized by a low expression of essential 
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effector molecules of apoptosis (BAK and BAX) and 
are thus apoptosis refractory [2]. On the contrary, 
hematopoietic organs are typically “primed” for apop-
tosis, i.e., there is only a minimal excess of anti- over 
pro-apoptotic proteins that enables cells of the hemat-
opoietic lineage to escape cell death [2]. External trig-
gers that lead to cellular stress or damage consequently 
lead to the rapid induction of apoptosis in primed 
cells.
Primed cells are marked by higher proliferation 
rates and present some of the features of tumor cells 
[1]. The abilities of malignant cells to evade cell death 
likewise depend on individual or multiple pro-survival 
proteins (MCL-1, BCL-2, BCL-xL) that bind to and 
sequester pro-apoptotic BH3-only activator as well as 
effector molecules [4]. The discrete pattern of BCL-2 
family dependencies is, however, remarkably hetero-
geneous between and within distinct neoplasias. Mod-
ern approaches such as BH3 profiling and large-scale 
CRISPR screens were able to shed light on the promi-
nent role of MCL-1 in tumor cell death evasion [5–7]. 
Figure 1 illustrates the dependencies of several cancer 
cell lines to MCL-1 or BCL-2 silencing using CRISPR/
Cas9 (data available at depmap.org) [8]. While solid 
tumors only displayed dependencies toward MCL-
1, hematological malignancies were dependent on 
both MCL-1 and BCL-2. This difference can be par-
tially explained by an increased level of priming that 
is seen in hematological cells. This dependency on 
MCL-1 is further driven by both genetic and func-
tional alterations in tumor cells that will be addressed 
in the current review and presented alongside upcom-
ing treatment strategies that specifically target MCL-1 
dependency in tumor cells. After a long journey of 
intensive drug development efforts (Fig. 2), potent and 
selective MCL-1 inhibitors were rapidly developed and 
are currently entering in clinical trials.
Multi‑functional roles of MCL‑1
Myeloid-cell leukemia 1 (MCL-1) was discovered, iso-
lated (and named) from the human myeloid leukemia cell 
line ML-1 [9]. MCL-1 was found to have close sequence 
similarities with BCL-2 and both genes shared “surpris-
ing” oncogenic properties: they sustained cell survival 
but did not promote cell proliferation [9]. Almost thirty 
years later BCL-2 and MCL-1 are the most prominent 
members of the BCL-2 family and well known for their 
anti-apoptotic role in health and disease.
MCL-1 shares the presence of BCL-2 homology 
regions (BH1-4) and a carboxy-terminal transmembrane 
localization domain with other pro-survival family mem-
bers (e.g., BCL-2 and BCL-xL) [10]. The alpha helix of the 
BH3 domain is essential for direct interactions between 
BCL-2 family members [11]. Anti-apoptotic family 
members including MCL-1 form a hydrophobic groove 
(composed of BH1-BH3 domains), where four hydro-
phobic binding pockets (P1–P4) guide the interaction 
with hydrophobic residues (h1-h4) of BH3 domains. In 
Fig. 1 Dependencies of tumor cell lines on MCL-1. Depmap analysis indicated that knockout of MCL-1 using CRISPR/Cas9 could significantly 
suppress the growth of both solid and blood cancers, the latter being more affected. Lower values indicate that a gene is more likely to be 
dependent in a given cell line. A score of 0 indicates non-essential genes whereas a score of -1 corresponds to the median of all common essential 
genes. Suppression of BCL-2 affected the survival of hematological tumor cell lines to a lesser extent, but had no effect on solid tumor cells (www.
depma p.org)
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addition, a conserved arginine within the BH1 domain is 
a key binding anchor for a conserved aspartate of BH3-
only proteins [10–12].
Irrespective of these similarities between distinct pro-
survival BCL-2 family members, MCL-1 differs in some 
key characteristics. MCL-1 is larger than other pro-sur-
vival BCL-2 family members. This is due to the presence 
of a N-terminal sequence rich in proline (P), glutamic 
acid (E), serine (S) and threonine (T) residues (PEST). 
The PEST sequence regulates MCL-1 turnover and the 
post-translational modifications (recently reviewed by 
Senichkin et al. [13]).
Moreover, sequence differences lead to a unique resi-
due profile within the BH3 binding groove and a more 
electropositive binding surface as compared to BCL-2 
and BCL-xL [12, 14]. This causes the unique binding 
affinity profile of MCL-1, with strong affinities for BAK, 
BIM, NOXA and PUMA, but only weak affinity for BMF 
and BAD. Direct sequestration of BAK and BIM is a key 
gatekeeper function of MCL-1 in the prevention of apop-
tosis. In turn, the BH3-only sensitizer protein NOXA 
specifically hinders MCL-1 from the exertion of its anti-
apoptotic functions, frees pro-apoptotic molecules and 
thereby initiates cell death [15, 16].
The importance of MCL-1 and its anti-apoptotic func-
tions for normal cellular development is demonstrated 
by numerous knockout studies. The inducible deletion of 
Mcl-1 during early lymphocyte differentiation increased 
apoptosis and arrested the development at pro-B-cell and 
double-negative T-cell stages. Induced deletion of Mcl-1 
in mature B- and T-cell populations resulted in their 
rapid loss [17]. Other conditional gene knockout studies 
demonstrated an essential role for MCL-1 in hematopoi-
etic stem cells, hepatocytes, neutrophils, cardiomyocytes 
and during neuronal development [18]. Moreover, sys-
temic deletion of MCL-1 in murine ES cells resulted in 
peri-implantation embryonic lethality [19]. Strikingly, 
MCL-1-/-blastocysts showed a maturation delay but no 
increase in apoptosis [19]. A similar observation was 
made in MCL-1 knockout studies in cardiomyocytes, 
where the simultaneous inhibition of apoptosis was not 
able to reverse the impact on mitochondrial structure 
and respiration [20]. This suggests that MCL-1 plays a 
role in cellular health and development that goes beyond 
its established pro-survival functions.
Several studies support central non-apoptotic roles of 
MCL-1. In addition to its outer mitochondrial membrane 
(OMM) localization, MCL-1 was shown to reside at the 
inner mitochondrial membrane (IMM) where it stabi-
lizes mitochondrial structures, mitochondrial fusion, 
ATP production, mitochondrial membrane potential and 
oxygen consumption rate [21]. Mechanistically, MCL-1 
was shown to directly interact with the mitochondrial 
fission and fusion regulators DRP-1 and OPA1 in human 
pluripotent stem cells (hPSCs), thereby influencing mito-
chondrial dynamics [22]. These results were recently con-
firmed in hPSC-derived cardiomyocytes, underlining the 
importance of MCL-1 for mitochondrial network organi-
zation. Interestingly, treatment of cardiomyocytes with 
the MCL-1 specific inhibitor S63845, but not venetoclax, 
significantly disrupted mitochondrial homeostasis [23]. 
The available information therefore strongly supports the 
idea that MCL-1 is not only a central antagonist of cell 
death, but also an essential molecule for normal mito-
chondrial function. Additional non-apoptotic functions 
of MCL-1 such as a role in the DNA damage response 
pathway or autophagy are currently emerging [24, 25]. 
Although these results provide exciting novel insights 
into the pleiotropic functions of MCL-1, they also raise 
concerns about the therapeutic window for MCL-1 
inhibitors. The close monitoring of patients will be key to 
guarantee the safety of this novel drug class, particularly 
in those receiving long-term treatment.
Fig. 2 Milestones in the development of MCL-1 inhibitors
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Overview of the role of MCL‑1 in cancer
Cell death evasion represents a cancer hallmark and it is 
therefore not surprising that several BCL-2 family mem-
bers play a central role in tumor formation and survival 
[26]. In contrast to other Bcl-2 family members, MCL-1 
is usually not involved in translocations; also mutations 
of MCL-1 are very infrequent (detected in approximately 
1% of all cancers) [27] although they were shown to pro-
long MCL-1 stability and affect the activity of MCL-1 
inhibitors [28]. However, MCL-1 stands out as it is one 
of the most frequently and highly amplified genes in 
human cancers [29]. The functional relevance of this fre-
quent upregulation of MCL-1 expression was verified 
in multiple tumor models: importantly, amplification of 
the MCL-1 gene locus (1q21.2) correlates with MCL-1 
dependency as evidenced by the impact of MCL-1 silenc-
ing [29]. Mice overexpressing MCL-1 in hematopoietic 
stem/progenitor cells are prone to malignant transforma-
tion, particularly (MYC-driven) lymphomas of the B-cell 
lineage [30, 31]. Accordingly, heterozygous loss of MCL-1 
was sufficient to inhibit MYC-driven lymphomagenesis 
in > 80% of Eμ-Myc;MCL-1 + / − mice. This was linked 
to the anti-apoptotic role of MCL-1 as concurrent loss 
of the BH3-only protein(s) BIM (and to a lesser extent 
PUMA) reversed this phenotype [32]. Additional tumor 
formation studies in mice confirmed an essential role for 
MCL-1 in the development of acute myeloid leukemia 
(AML), T-cell lymphomas and breast cancer [33, 34].
The striking impact of perturbing MCL-1 dependency 
on tumor development underscores the need of tumor 
cells to sustain MCL-1 expression and stability. Due to 
the short half-life of MCL-1 (typically referred to as < 1 h) 
[36], MCL-1-dependent leukemic cells are more sensitive 
to chemotherapy as compared to BCL-2 dependent cells 
[37, 38]. Given the lack of recurrent MCL-1 mutations, 
tumor cells require alternative mechanisms to over-
come this vulnerability in order to sustain MCL-1 activ-
ity. Multiple adaptation processes have been described 
that culminate in enhanced MCL-1 stability, including 
the deregulation (either over- or underexpression), post-
translational modifications as well as mutational events 
of molecules involved in MCL-1 degradation and/or 
stabilization.
The rapid degradation of MCL-1 in the presence of 
therapeutic pressure is catalyzed via the ubiquitin–pro-
teasome pathway. MCL-1 ubiquitin ligase E3 (Mule) and 
the Skp1-Cullin-F box (SCF) E3 ligase substrate receptors 
F-box and WD repeat domain-containing 7 (FBW7) and 
β-TrCP are among the best studied mediators of MCL-1 
ubiquitination (reviewed in Ref [13]). The binding of 
FBW7 to MCL-1 is facilitated via the phosphorylation of 
the PEST sequence of MCL-1, leading to ubiquitination 
and proteasomal degradation (Fig.  3). The introduction 
of mutations within the PEST sequence blocks this phos-
phorylation process and results in an increased MCL-1 
half-life and increased sequestration of PUMA. Mitotic 
arrest induced by microtubule-targeting agents leads to 
the rapid phosphorylation within the PEST sequence and 
subsequent recognition and ubiquitination by  SCFFbw [7]. 
However, FBW7-deficient tumor cells (by deletion or loss-
of-function mutations) acquire a resistance to anti-tubu-
lin chemotherapeutics. Moreover, these tumors are prone 
to therapy-induced polyploidy after mitotic slippage [39]. 
In T-cell acute lymphoblastic leukemia (T-ALL), FBW7 
mutations are found in up to 25% of T-ALL patients 
[40]. Here,  SCFFbw [7] targets MCL-1 for destruction in a 
GSK3β dependent manner and is involved in drug resist-
ance and tumor formation [41].
Apart from the genetic inactivation of E3 ligase com-
ponents, tumor cells use dynamic processes that inter-
fere with the proteasomal degradation of MCL-1. The 
prolyl isomerase Pin1 was found to directly bind to 
FBW7 in a phosphorylation dependent manner induc-
ing FBW7 auto-ubiquitination and degradation. Genetic 
loss of Pin1 therefore leads to elevated FBW7 protein 
levels, loss of MCL-1 and sensitization to taxol [42]. In 
addition, the deubiquitinase USP9X was found to bind 
and remove polyubiquitin chains from MCL-1 targeted 
for degradation [36]. USP9X expression correlated with 
MCL-1 overexpression and/or poor outcome in follicular 
lymphoma, diffuse large B-cell lymphoma (DLBCL) and 
multiple myeloma (MM) [36]. Conversely, knockdown 
or therapeutic targeting of USP9X destabilizes MCL-1 
and sensitizes tumor cells to BCL-2/BCL-xL inhibitors 
[36, 43]. More recently, USP24 and USP13 were likewise 
shown to interact, deubiquitinase and stabilize MCL-1, 
thereby mediating BH3 mimetic and USP9X inhibitor 
resistance [43, 44].
Finally, MCL-1 is not only important for tumor devel-
opment and initial drug sensitivity. MCL-1 is a central 
driver of drug resistance against a plethora of established 
cancer treatments. As one might expect, MCL-1 drives 
resistance to BCL-2 and BCL-xL targeting compounds. 
Overexpression of MCL-1 promoted drug resistance of 
both solid tumors and hematological malignancies to var-
ious chemotherapeutic agents. Interestingly, MCL-1 in 
cooperation with MYC induced drug resistance in triple-
negative breast cancer via upregulation of mitochondrial 
oxidative phosphorylation and expansion of cancer stem 
cells. [45] A role for metabolic pathways in MCL-1-asso-
ciated drug resistance is supported by additional studies. 
In ALL, the mTOR inhibitor rapamycin was revealed to 
modulate glucocorticoid sensitivity via downregulation 
of MCL-1 [46]. Moreover, combined inhibition of glyco-
lysis and OXPHOS indirectly affects MCL-1 expression 
and thus induces cell death in tumor cells [47].
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These results illustrate the numerous implications of 
MCL-1 in promoting cancer survival and drug resistance. 
Nevertheless, our current knowledge about the regula-
tion of BCL-2 family members in cancer clearly dem-
onstrates that the efficacy of MCL-1 targeting strategies 
will depend on 1) the level of apoptotic priming and 2) 
the MCL-1 dependency status [6, 48]. In addition, limited 
single-agent activity of MCL-1 inhibitors can be boosted 
with rationale combination approaches such as MEK 
inhibitors in KRAS-mutant non-small-cell lung cancer 
(NSCLC) [49]. A detailed knowledge of tissue-dependent 
BCL-2 family dependencies in concert with treatment 
decisions on a case by case basis therefore offers the 
chance for the implementation of true precision medi-
cine approaches.
Solid tumors
Preclinical studies with “modern” MCL-1 inhibitors 
strongly pointed to hematological malignancies as prime 
indications for early clinical testing. However, a limited 
number of studies also highlighted an MCL-1 depend-
ency in solid tumors such as NSCLC and breast cancer 
cell lines, opening new avenues for the evaluation of 
MCL-1 inhibitors in these cancers. Moreover, MCL-1 has 
been identified as an important biomarker: its expres-
sion, generally evidenced by immunohistochemistry, 
was associated with resistance to therapy and reduced 
progression-free survival (PFS) and overall survival (OS). 
As high MCL-1 expression often results in resistance to 
both cytotoxic agents and targeted therapies, combining 
MCL-1 inhibitors with these agents is generally able to 
overcome this resistance. We will now discuss the find-
ings supporting the implication of MCL-1 in an array of 
solid and hematological tumors and review the potential 
combinations of MCL-1 inhibitors with preexisting ther-
apeutic options.
Lung cancer
Lung cancer consists of approximately 80% NSCLC and 
20% small-cell lung cancer (SCLC) and remains the lead-
ing cause of cancer-related deaths. NSCLC is commonly 
associated with targetable kinase mutations that are less 
present in SCLC biology. Sixty-two percent of patients 
with NSCLC harbor an oncogenic driver mutation and 
half of them consist of a therapeutically targetable lesion 
[50, 51]. Mutations in KRAS and EGFR are the most 
common and occur in 25–30% or 11–15% of patients, 
respectively. Regarding treatment, the development of 
Fig. 3 Direct and indirect targeting of MCL-1. (a) There are two principal approaches in the targeting of MCL-1: indirect inhibition through inhibition 
of transcription or translation and downregulation of MCL-1 via targeting of proteasomal degradation and direct inhibition through interruption 
of protein–protein interactions via small molecule inhibitors (BH3-mimetics). (b) At the mitochondrial membrane, MCL-1 binds the proapoptotic 
multidomain effector BAK to prevent cell death. In primed cells, there is only a minimal excess of anti- over pro-apoptotic proteins. A variety of cell 
stressors increase the expression of the proapoptotic sensors, including the BH3-only proteins (i.e., BIM, BID, PUMA, NOXA and BAD). The treatment 
with an MCL-1 inhibitor will liberate BAK from binding to MCL-1. BAK will oligomerize and form pores in the mitochondrial membrane leading to 
cytochrome c release into the cytosol and activation of the caspase cascade. (c) MCL-1 can be phosphorylated by several protein kinases which 
enables the recognition of MCL-1 by its E3 ubiquitin-ligases TrCP or FBW7. In addition, the E3 ubiquitin-ligase Mule can interact either with the 
C- or N-terminus of MCL-1 in a phosphorylation-independent manner. This binding can be inhibited by BIM and PUMA or increased by NOXA. 
Ubiquitination of MCL-1 targets it for proteasomal degradation. It can be opposed by the deubiquitinases such as USP9X that directly removes 
polyubiquitin chains, which results in MCL-1 stabilization
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EGFR- tyrosine kinase inhibitors (EGFRi) resulted in 
some success, but the observed responses were short, 
due to the development of acquired resistance resulting 
from secondary or tertiary EGFR mutations and other 
mechanisms [52]. After exposure to EGFR inhibitors, 
EGFR-mutant NSCLC cells lose their ability to undergo 
apoptosis, partially due to the high expression of MCL-1 
and finally become “drug-tolerant cells.” This overexpres-
sion is explained by (1) enrichment of cells with preex-
isting high MCL-1 expression and (2) activation of the 
mTORC1/eIF4E-mediated cap-dependent translation 
pathway that controls MCL-1 expression [52]. Combin-
ing MCL-1 and EGFR inhibitors synergistically reduced 
viability, induced apoptosis and prevented the devel-
opment of drug-tolerant cells. This combination also 
reduced subcutaneous tumors in xenograft models with 
EGFR-mutated cell lines [52].
Micro-array and immunohistochemistry demonstrated 
high MCL-1 expression in NSCLC cells and its inhibition 
could induce NSCLC cell apoptosis [53]. In tissue sam-
ples of NSCLC, the expression of MCL-1 could be cor-
related to the proliferation and apoptosis index and serve 
as a biomarker for survival: the five-year OS of patients 
with MCL-1 positive staining (68.3%) was inferior as 
compared to the survival of those with MCL-1-negative 
tumors (93.1%) [54]. The expression of MCL-1 in SCLC 
has been studied to a lesser extent. SCLC is generally 
characterized by a heterogeneous BCL-2 family depend-
ency. Seven studied SCLC cell lines displayed differential 
addiction to either BCL-2, BCL-xL  or MCL-1 for their 
survival, and the predominant protein expression of 
BCL-2, BCL-xL or MCL-1 could be used as a surrogate 
marker for this selective addiction [55]. High expression 
of MCL-1, associated with low expression of BCL-xL and 
BCL-2, was recently described in a small series of SCLC 
biopsies [56]. The MCL-1 inhibitor S63845 reduced via-
bility of SCLC cell lines in  vitro with an IC50 of 23 to 
78 nM by inducing apoptosis, while in vivo treatment of 
two xenograft models reduced tumor volumes to a com-
parable degree as cisplatin in combination with etopo-
side [56]. SCLCs with high BCL-xL expression were less 
sensitive to S63845 and its knockdown sensitized cells 
to MCL-1 targeting. Accordingly, the combination of 
navitoclax (a dual inhibitor of BCL-xL  and BCL-2) and 
S63845 reduced the cell viability of SCLC cell lines and 
showed in  vivo synergistic effects in S63845-resistant 
xenograft model [56].
Additional evidence for the attractive role of MCL-1 as 
a drug target in lung cancer comes from its non-apoptotic 
involvement in DNA repair. Targeting of MCL-1 with a 
small molecule inhibitor (MI-233) blocked MCL-1-medi-
ated HR DNA repair and thereby sensitized cancer cells 
to treatment induced replication stress [24]. Remarkably, 
this strategy was effective in vivo as evidenced by strong 
synergism of MI-233 with either hydroxyurea or olapa-
rib in lung cancer models. Although it needs to be proven 
whether these effects can be replicated with established 
MCL-1 inhibitors, these results demonstrate that the 
non-apoptotic functions of MCL-1 can be exploited to 
tackle key vulnerabilities of lung cancer cells.
Breast cancer
Similar to other malignancies, breast cancer is a het-
erogeneous disease that encompasses distinct molecular 
subtypes. In the majority of mammary carcinomas, a sig-
nificant portion of the malignant cells express hormone 
receptors for estrogen and/or progesterone. Importantly, 
BCL-2 is a direct transcriptional target of ERα and its 
expression is predominantly found in this subgroup [57].
In contrast, MCL-1 is widely expressed in all breast 
cancers: estrogen-receptor-positive (ER +) breast can-
cers, HER2-amplified and triple negative breast cancers. 
Alterations in regulatory pathways as well as external sig-
nals can modulate MCL-1 expression. This was elegantly 
illustrated by Louault et al. who showed that primary cul-
tures of cancer-related fibroblasts (CAFs) protect breast 
cancer cells from chemotherapy-induced apoptosis [58]. 
Co-culture experiments with CAFs suggest that the 
increased MCL-1 mRNA expression and protein stability 
in cancer cells are the result of IL-6 release [58].
High levels of MCL-1, assessed by immunohistochem-
istry, could be correlated with high tumor grade, whereas 
low expression of MCL-1 was correlated with low tumor 
grade [59]. Accordingly, patients’ survival is decreased 
significantly with increased expression of MCL-1 [59]. 
Quantification of RNA expression of the BCL-2 fam-
ily proteins (BCL-2, MCL-1 and BCL-xL) in breast can-
cer cell lines and primary patient samples found higher 
MCL-1 transcripts compared to BCL-2 and BCL-xL [60]. 
Moreover, MCL-1 protein expression levels are linked to 
poor outcome, are required for breast cancer develop-
ment, and targeting of MCL-1 hampers triple-negative 
breast cancer development in vivo [30].
Molecular profiling of tumor cells persisting after neo-
adjuvant chemotherapy for triple-negative breast cancer 
showed amplifications of MYC(54%) and MCL-1(35%) 
[61]. In this study, 83% of MYC-amplified tumors exhib-
ited co-amplification of MCL1, suggesting that MYC and 
MCL-1 cooperate to induce chemoresistance [61]. In a 
follow-up study, the authors identified an increased mito-
chondrial oxidative phosphorylation and the generation 
of reactive oxygen species as driving mechanisms of this 
MYC and MCL-1 induced resistance [45].
Targeted MCL-1 blockade using RNAi also increased 
caspase-mediated cell death in ERα + breast cancer cells, 
resulting in sustained growth inhibition [60]. Strikingly, 
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ERα + breast cancer cell lines have limited sensitivity to 
BCL-2 inhibitors. The addition of ABT-263 to cultures 
of breast cancer cells results in a transient apoptosis 
induction, due to a rapid upregulation of MCL-1 and 
subsequent sequestration of BIM by MCL-1. When the 
mTORC1 inhibitor RAD001 was added to ER + breast 
cancer cells, the MCL-1 protein levels decreased and cells 
were able to undergo apoptosis [62]. The combination of 
ABT-263 with the specific MCL-1 inhibitor VU661013 
was able to induce tumor cell death in vivo and a syner-
gistic reduction in tumor growth [62].
Similar efficacy was seen when potent MCL-1 inhibi-
tors are combined with standard therapeutics, incl. 
tamoxifen, trastuzumab, paclitaxel or docetaxel [63, 64]. 
This suggests that rationale derived combination thera-
pies using the blockade of MCL-1 can induce cell death 
in all breast cancer subtypes in addition to single-agent 
MCL-1 inhibitor approaches in tumor clones with strong 
MCL-1 dependency.
Melanoma
The introduction of immunotherapy and novel therapeu-
tics (BRAF and MEK inhibitors) has improved the out-
come of melanoma patients. However, disease relapse 
typically occurs due to acquired resistance through 
reactivation of ERK1/2 signaling [65]. ERK1/2 promotes 
cell survival in BRAF- or KRAS-mutant tumor cells by 
increasing the expression of pro-survival BCL-2 proteins 
and further stabilizes the MCL-1 protein [66].
Melanoma cells exhibit high levels and activity of 
MCL-1 protein [67, 68]. Activation of BRAF signaling 
results in increased expression of MCL‐1 in vitro, reveal-
ing a potential mechanism of apoptotic resistance [69]. 
Similar to other malignancies, knockdown of MCL-1 sen-
sitizes melanoma cells to various treatments, including 
BRAF or MEK inhibitors. When different BH3-mimetics 
were tested on melanoma cell lines (including wild-type 
and mutant BRAF and NRAS lines), all cell lines were 
found to be resistant to the individual drugs. Combina-
tions targeting MCL-1 plus BCL-xL or BCL-2 showed 
considerable synergistic killing activity that was elicited 
via both BAX and BAK. This synergy was also observed 
in 3D spheroid cultures, where BH3-mimetic combina-
tions targeting MCL-1 plus BCL-xL were most effective 
at killing melanoma cells.
The power of combination approaches with BH3-
mimetics in melanoma is further supported by another 
recent study that investigated mRNA and protein expres-
sion levels of MCL-1 and BCL-xL in different cancer 
models. Compared to other cancers, the MCL-1:BCL-xL 
mRNA and protein ratio was 2 to sixfold higher in mela-
noma. Because BCL-xL levels were lower in melanoma, 
these results indicated that MCL-1 was predominant 
in melanoma cell lines and patient samples [70]. The 
combined inhibition of ERK1/2 signaling together with 
MCL-1 induced synergistic apoptosis, inhibited the clo-
nogenic survival of melanoma cells and caused regression 
of subcutaneous tumors in xenografts. Finally, combin-
ing MCL-1i with either BRAF or MEK inhibitors re-
sensitized melanoma cells and enhanced tumor growth 
inhibition in  vivo. While monotherapy with the BRAFi 
vemurafenib or the MEKi trametinib showed no anti-
tumor effects in BRAF-mutant xenograft models, the 
combination of the MCL-1i AZD5991 with these inhibi-
tors reduced tumor growth [70].
Colorectal cancer
MCL-1 also protects colorectal cancer (CRC) cells from 
apoptosis [71]. Immunohistochemistry on tumor biop-
sies showed strong cytoplasmic expression of MCL-1 
that could be correlated with tumor stage, lymph node 
metastasis and with inferior survival of CRC patients 
[71]. MCL-1 also protects CRC tumor cells from the 
apoptotic effects of targeted drugs. Indeed, several inhib-
itors of aberrantly activated oncogenic kinases (such as 
the multi-kinase inhibitor regorafenib and its analogue 
sorafenib) are used in chemotherapy-resistant and meta-
static colorectal cancer as well as in other gastrointestinal 
malignancies. Early work showed that sorafenib acts by 
inhibiting the initiation factor eIF4E and subsequently 
decreasing MCL-1 protein levels [72]. Constitutive over-
expression of MCL-1 in CRC cells significantly inhibits 
sorafenib-induced apoptosis, whereas MCL-1 down-reg-
ulation by RNA interference enhances sorafenib-induced 
apoptosis [73].
Lin Zhang et al. extensively dissected the mechanisms 
of resistance that CRC cells acquire toward regorafenib. 
They first identified that inactivating mutations in the 
previously described FBW7 gene contribute to resistance 
to these multi-kinase inhibitors [74]. Analysis of BCL-2 
family members revealed a dose- and time-dependent 
depletion of MCL-1 in regorafenib-treated wild-type 
CRC cells. Clones with hotspot mutations in the FBW7 
gene do not show this MCL-1 depletion and thus sur-
vive and become dominant upon chronic drug expo-
sure. MCL-1 knockout in CRC cells or the addition of an 
MCL-1 inhibitor confirmed the critical role of MCL-1 in 
apoptosis. In both experiments, the sensitivity toward 
regorafenib was restored in each of the resistant cell lines 
[74].
In a follow-up study, regorafenib was found to 
inhibit upstream ERK signaling and to activate GSK3β-
mediated MCL-1 phosphorylation [75]. In line with 
this,  BRAFV600E mutations in CRC cells were associated 
with MCL-1 upregulation, stabilization via phospho-
rylation at Thr163 and chemoresistance [76, 77]. This 
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vicious cycle can be targeted with trametinib which was 
shown to enhance FBW7-mediated MCL-1 degradation 
(via the phosphorylation of the PEST sequence) in CRC 
cells [78]. Mutations within the PEST sequence blocked 
this phosphorylation process and resulted in increased 
MCL-1 half-life, increased sequestration of PUMA and 
resistance to regorafenib [79]. Interestingly, the MCL-1 
inhibitors S63845, AZD5991 or AMG176 restored the 
sensitivity to regorafenib in both CRC cells with intrinsic 
FBW7 mutations or acquired mutations in MCL-1 in dif-
ferent in vitro and in vivo experiments [79]. In resistant 
CRC cells, immunoprecipitation studies found a strong 
binding of MCL-1 to the proapoptotic BH3-only pro-
tein PUMA that was disrupted after treatment with the 
MCL-1 inhibitor S63845. These results confirm that two 
events are necessary for initiating apoptotic response to 
regorafenib, including early MCL-1 degradation and later 
PUMA induction.
Hematological Malignancies
During lymphoid and myeloid differentiation, the expres-
sion of BCL-2 family proteins is highly variable. During 
B-cell development, MCL-1 is implicated in every differ-
entiation step: it is essential for germinal centre forma-
tion and maintenance, memory B-cell development and 
survival of plasma cells [80]. In contrast, BCL-2 is impor-
tant for naïve and memory B-cells, but is downregulated 
in the germinal center. Most of the B-cell malignancies 
mimic the BCL-2 family expression profile of their nor-
mal counterparts [80]. Further evidence that the cell of 
origin plays an important role in anti-apoptotic depend-
encies and BH3 mimetic sensitivity comes from studies 
in AML and T-ALL [81, 82]. The observed responses to 
a combination therapy of venetoclax and azacitidine for 
AML correlated closely with the developmental stage, 
where phenotypically primitive AML was sensitive, but 
monocytic AML was more resistant [82]. The latter had 
a distinct transcriptomic profile with loss of BCL-2 and 
gains of MCL-1 for their survival. Similarly, the matu-
ration stage of T-ALL determined its anti-apoptotic 
dependency and sensitivity to BH3-mimetics. Mitochon-
drial BH3 profiling showed that most of T-ALL cells were 
dependent upon BCL-XL, except an early T-cell progeni-
tor subgroup that was dependent on BCL-2 [81].
Multiple myeloma
MM is thought to represent a prime example of an 
MCL-1-dependent malignancy, which might arise from 
the crucial role of MCL-1 for the survival of normal 
plasma cells [83]. This is underlined by the impressive 
impact of MCL-1 targeting strategies. Initial preclinical 
efforts demonstrated that only MCL-1, but not BCL-2 
or BCL-xL targeting anti-sense oligonucleotides are 
capable to impair MM cell survival [84, 85]. A find-
ing that is supported with today’s clinical-grade BH3-
mimetics. Although promising results were obtained in 
a subset of MM patients treated with venetoclax, this 
activity is restricted to tumor clones with high BCL-
2:MCL-1 and BCL-2:BCL-xL expression ratios as well 
as reduced electron transport chain activity [86, 87]. 
This venetoclax-sensitive phenotype is enriched in MM 
patients with tumor clones carrying a t(11;14) [88]. In 
contrast, most other MM subgroups rely on MCL-1 
and are thus insensitive to single-agent BCL-2 or BCL-
xL inhibition as evidenced by pharmacological inhibi-
tion and CRISPR screens [7].
The analysis of BCL-2 family members in primary 
MM cells strengthens the predominant role of MCL-1. 
Increased MCL-1 expression discriminates MM cells 
from “normal” plasma cells and is linked to poor out-
come [89]. Interestingly, MCL-1 dependency is further 
enhanced during disease progression. Gomez-Bougie 
et  al. observed a 36% increase of MCL-1-dependent 
MM cells from diagnosis to relapse based on BH3 
mimetic activity results [90]. Accordingly, BH3 profil-
ing and interaction analyses of pro- and anti-apoptotic 
BCL-2 family members (e.g., MCL-1/BCL-xL/BCL-2 
binding to Bim) predict the efficacy of BH3-mimetics in 
MM [6, 91]. Conflicting results exist in relation to the 
impact of amplification of 1q21 and MCL-1 inhibitor 
sensitivity [92, 93].
MCL-1 in myeloma is regulated at both the transcrip-
tional and the functional levels. The major MM survival 
factor interleukin 6 (IL-6) and interferon alpha (IFNa) 
were shown to promote MCL-1 protein expression in 
a STAT3-dependent manner, but not those of other 
BCL-2 family members [94]. Alternative extracellular 
triggers of increased MCL-1 expression include VEGF, 
BAFF, APRIL and sphingosine-1-phosphate. Gain of the 
chromosomal region 1q21 and deregulation of MCL-1 
targeting miRNAs were likewise shown to contribute 
to aberrant MCL-1 expression in MM cells [93]. More 
recently, IL-6-induced MCL-1 dependency in MM was 
linked to its concurrent reliance on bone marrow stromal 
support. Gupta et al. were able to demonstrate that IL-6 
alters the phosphorylation status of BIM in myeloma cells 
and thereby promotes the formation of MCL-1:BIM com-
plexes (which outcompetes BCL-2 or BCL-xL binding to 
BIM) at least in part in a MEK signaling-dependent man-
ner [95]. Noteworthy, this IL-6-induced functional switch 
in favor of MCL-1 dependency is independent of changes 
in the MCL-1 expression levels. MM cells—in turn—also 
alter their surrounding environment to stimulate the for-
mation, functionality and survival of myeloid suppressor 
cells via upregulation of MCL-1 through STAT3/STAT1 
activation [96]. Consequently, MCL-1 also appears as an 
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attractive drug target to overcome the immunosuppres-
sive features within the myeloma niche.
Finally, MCL-1 plays not only a role in myeloma sur-
vival and drug resistance but also in the efficacy of estab-
lished drugs. The presence of a short, cleaved form of 
MCL-1 was implicated in both melphalan and borte-
zomib induced apoptosis in MM cells. Melphalan expo-
sure induces the dissociation of MCL-1 (but not BCL-2) 
from BIM and the caspase dependent cleavage of MCL-1 
into its pro-apoptotic form. This leads to the release of 
BIM and the exertion of its pro-apoptotic function [97]. 
Proteasome inhibitors were likewise shown to induce 
caspase dependent MCL-1 cleavage. This went in line 
with a prominent upregulation of NOXA, increased pres-
ence of MCL-1:NOXA complexes, release of BIM from 
MCL-1 and induction of apoptosis [98, 99]. In addition, 
nuclear translocation of MCL-1 was reported to induce 
apoptosis via c-Jun upregulation [100]. The short half-life 
of MCL-1 also affects the potency of mitotic inhibitors in 
myeloma. Mitotic arrest leads to a rapid loss of MCL-1 
and induction of apoptosis in myeloma cells, whereas 
MM cells with sustained expression of anti-apoptotic 
molecules (e.g., BCL-xL) or the capability to evade via 
mitotic slippage are less prone to mitotic blockers [101]. 
Overall, these data demonstrate a key role for MCL-1 in 
myeloma cell survival and for the efficacy of established 
backbone therapeutics in MM.
Non‑Hodgkin lymphoma
The importance of MCL-1 as a potential therapeutic 
target in lymphoma is underscored by the limited clini-
cal success of the BCL-2-inhibitor venetoclax, which 
achieved an overall response rate of 44% in a phase 1 clin-
ical trial in Non-Hodgkin lymphoma (NHL) (MCL, 75%; 
FL, 38%; DLBCL, 18%) [102] and 26% in a real-world off-
label NHL patient cohort [103]. MCL-1 has been iden-
tified as a resistance factor for venetoclax in multiple 
studies [104–106], indicating that survival of lymphoma 
cells can be mediated by both BCL-2 and MCL-1.
Screening of a large tumor cell line panel comprising 
952 cancer cell lines, across different malignancies for 
their sensitivity to a precursor of AMG-176 (AM-8621), 
identified B-cell lymphoma as most dependent on MCL-
1, next to MM [107]. Of note, this screen also included 
venetoclax and thus allowed for a direct comparison of 
BCL-2 and MCL-1 as therapeutic targets. B-cell lym-
phoma comprises Hodgkin lymphoma as well as NHL, 
with DLBCL being the most aggressive type of NHL. 
Among the DLBCL cell lines included in this panel, sev-
eral cell lines displayed a dependency on MCL-1, BCL-2, 
both, or neither BCL-2 nor MCL-1, highlighting the het-
erogeneity of this disease in regard to the BCL-2 family 
[107]. This heterogeneity was also observed in a study 
investigating the function of the different anti-apoptotic 
BCL-2 proteins in DLBCL by comparing the efficacy of 
different BH3-mimetics [108]. Of note, when compar-
ing the mRNA expression of the main anti-apoptotic 
BCL-2 proteins in a large cohort of primary DLBCL tis-
sues, expression of MCL-1 was higher and more homog-
enously high than expression of BCL-2 or BCL-xL. These 
data demonstrate that although MCL-1 is expressed 
rather uniformly at high levels at the mRNA and pro-
tein level, only a subset of cells are dependent on MCL-1 
and sensitive to MCL-1-inhibition. Sensitivity to MCL-
1-inhibitors is influenced by the expression of other 
anti-apoptotic BCL-2 proteins, but also by the interac-
tion pattern of MCL-1 with pro-apoptotic BH3-domain 
containing proteins [108]. Of note, two independent 
studies have identified high expression of BCL-xL as the 
most predictive factor for resistance to MCL-1-inhibi-
tors, indicating that BCL-xL (but not BCL-2) can func-
tionally compensate for the inhibition of MCL-1 [107, 
109]. However, these correlation analyses have not yet 
been performed in larger panels of lymphoma cells, and 
a comparison across different tumor types in particular 
when including solid tumors may underestimate a poten-
tial role of BCL-2.
Primary effusion lymphoma is a rare subtype of DLBCL 
that currently has limited treatment options and occurs 
in individuals with Kaposi’s sarcoma-associated herpes-
virus. A recent CRISPR/Cas9 knockout screen identified 
MCL-1 as a key anti-apoptotic driver in primary effusion 
lymphoma, highlighting the potential of MCL-1-inhibi-
tors as novel therapeutic option in this aggressive malig-
nancy [110].
Early clinical data as well as preclinical data indi-
cate that also in mantle cell lymphoma, which is largely 
characterized by high expression of BCL-2 and showed 
a more promising clinical response to venetoclax than 
other subtypes of B-cell lymphoma [102], MCL-1 may be 
a valuable therapeutic target. This may be particularly the 
case in the context of acquired resistance to venetoclax, 
which has been described to be associated with a shift 
toward MCL-1-dependency [111]. Therefore, inhibition 
of MCL-1 may be a particularly promising strategy in 
patients that relapse after venetoclax treatment. Preclini-
cal data indicate a high level of synergy between MCL-
1- and BCL-2-inhibition, and clinical trials investigating 
the combination of BCL-2- and MCL-1-inhibition are 
currently ongoing. However, this treatment is anticipated 
to be associated with increased toxicity on normal blood 
cells, and it remains to be determined under which con-
ditions a safe therapeutic window can be achieved.
Interestingly, early observations indicate that c-MYC-
driven Burkitt lymphoma may be particularly dependent 
on MCL-1, with 7 out of 7 tested cell lines responding 
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to nanomolar concentrations of S63845 [109]. This link 
between c-MYC-driven cancers and a dependency on 
MCL-1 was confirmed by genetic studies, where het-
erozygous deletion of MCL-1 resulted in diminished 
growth of c-MYC-driven lymphomas [112].
Chronic lymphocytic leukemia
Inefficient apoptosis is a hallmark of chronic lymphocytic 
leukemia (CLL). Overexpression of the anti-apoptotic 
protein BCL-2 is considered primarily responsible for the 
increased apoptosis resistance and prolonged survival of 
CLL B cells and explains the rationale of using a specific 
BCL-2 inhibitor (venetoclax) in CLL. The approval and 
current use of venetoclax in the treatment of CLL gener-
ated interest in studying and targeting the other BCL-2 
family proteins. Early work showed high mRNA and 
protein levels of MCL-1 in CLL cells [113]. These levels 
could be correlated to resistance to chemotherapeutic 
agents and monoclonal antibody therapy with rituximab 
[113, 114]. In this context, stromal-driven drug resist-
ance was shown to be a mediator of MCL-1-associated 
chemo-resistance. Co-culture of CLL cells with stromal 
cells induces MCL-1 mRNA and protein expression in 
concert with AKT, ERK and GSK3β phosphorylation, 
regulating MCL-1 expression and protein [115].
The B-cell receptor is a key signaling molecule that 
triggers pathways that can induce B-cell proliferation, 
survival, differentiation, anergy and apoptosis. Sustained 
engagement of the BCR induces MCL-1 through activa-
tion of PI3 kinase and results in resistance toward chem-
otherapy [116]. Its downstream signaling can be blocked 
with the Bruton tyrosine kinase-inhibitor ibrutinib. Acti-
vation of the BCR protected CLL cells from venetoclax-
induced apoptosis through induction of MCL-1. This 
dependency on MCL-1 was confirmed by siRNA knock-
down of MCL-1 that completely reversed resistance of 
BCR-activated CLL cells to venetoclax [117]. High levels 
of MCL-1 were shown to inversely correlate with treat-
ment response in the phase 1 study of ABT-263 in CLL 
[118]. Finally, different signaling inhibitors (BTK, PI3 
kinase and SYK kinase inhibitors) could overcome BCR-
mediated venetoclax resistance [117].
Targeting MCL-1 directly with selective inhibitors, 
or indirectly with agents that cause downregulation of 
MCL-1 as part of their mechanism of action, proved to 
be efficient in preclinical models of CLL [119, 120]. More 
recently, new MCL-1 inhibitors were preclinically tested 
in CLL. One of them, AMG 176, was able to induce cell 
death at nanomolar concentrations; this effect was seen 
in monocultures of primary CLL cells and in co-cultures 
with stromal cells. Only minor differences were observed 
in different cytogenetic subtypes of CLL. AMG 176 
induced CLL cell death via the mitochondrial pathway 
with an increase of BAX and BAK in the mitochondrial 
protein fraction, indicating oligomerization of these pro-
teins. Finally, a synergistic effect was observed between 
venetoclax and AMG-176 [121].
Acute myeloid leukemia
The approval of venetoclax plus hypomethylating agent 
or low dose cytarabine for acute myeloid leukemia 
(AML) has brought forth a new treatment landscape for 
this disease [122, 123]. Nevertheless, many patients will 
not respond or will eventually relapse. While the mech-
anisms of resistance to venetoclax in AML may vary, 
resistance is primarily believed to be driven by a shift 
in dependency to other anti-apoptotic factors such as 
MCL-1. Recent investigations, however, have highlighted 
enrichment of clones driven by enhanced FLT3 or RAS 
signaling, or biallelic loss of TP53 in AML patients who 
have acquired or had primary resistance to venetoclax 
[124]. High levels of MCL-1 expression were identified 
in AML clones with internal tandem duplications (ITD) 
of FLT3. Upregulation of MCL-1 in FLT3-ITD clones is 
driven by constitutive STAT3 and/or STAT5 signaling 
and correlates with functional MCL-1 dependency as 
evidenced by cell death induction in response to MCL-1 
silencing [125, 126].
Hierarchical analysis of major pro-survival proteins 
in murine and human AML likewise demonstrated that 
MCL-1 is the major anti-apoptotic protein in AML. 
Glaser et al. showed that Mcl-1 was critical for the sus-
tained survival and expansion of mouse as well as human 
AML, whereas Bcl-xL, Bcl-w or Bcl-2 only play minor 
prosurvival roles in these cancers [33]. This observation 
was independent of the mutational status of the tested 
cell lines, and only apoptosis refractory cells (i.e., cells 
harboring BAX/BAK downregulation or BAK muta-
tion) remained viable in the absence of MCL-1 [33]. 
In accordance with these findings, MCL-1 upregula-
tion is frequently found at disease recurrence [127] and 
high levels of MCL-1 are linked to poor outcome.[128]. 
In contrast to this, mitochondrial priming measured by 
BH3 mimetic peptides showed primary AML cells from 
both refractory and sensitive patients responded more 
to the BAD BH3 peptide, which suggested a specific 
dependence on BCL-2 or BCL-w for these cells’ survival. 
These results, coming from conditional knock-out and 
from mitochondrial priming studies, indicate that there 
are different subgroups in AML with reliance on different 
anti-apoptotic proteins.
More recent data provided important insights into the 
dynamics of BCL-2 family members in different sub-
groups of AML. This revealed a heterogeneous expres-
sion profile of BCL-2 and MCL-1, with clear upregulation 
of the latter in monocytic AML. Intriguingly, monocytic 
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AML is venetoclax resistant which relies on its depend-
ency on MCL-1 for oxidative phosphorylation and sur-
vival [82, 129].
This culminative evidence highlights the essential role 
of MCL-1 in the development and sustained growth of 
AML and thus places AML at the center of the ongoing 
implementation studies of MCL-1 targeting therapeutics.
The clinical exploration of MCL-1 inhibitors in AML 
is further supported by impressive preclinical in  vitro 
and in vivo results with modern MCL-1 targeting BH3-
mimetics. AML together with myeloma was revealed as 
the prime indication for these drugs (cfr Table  2). Also, 
side by side comparisons of BH3-mimetics targeting 
MCL-1, BCL-2 or BCL-xL underlined the role of MCL-1 
as key target in AML [130]. MCL-1 inhibitors rapidly 
induce apoptosis in AML cells in a BAK dependent man-
ner. This established activity profile together with its role 
in drug resistance makes it an attractive target for com-
bination therapy approaches. For instance, venetoclax 
induces apoptosis in a BAX-dependent manner [130]. 
Therefore, several clinical trials are currently exploring 
the impact of simultaneous BCL-2 and MCL-1 inhibi-
tion in AML. These efforts are supported by encouraging 
preclinical data demonstrating the feasibility and potent 
activity of this combination approach [131]. Moreover, 
combined BCL-2 + MCL-1 inhibition outperformed the 
activity of standard drugs.
Regarding the treatment of recurrent disease, MCL-1 
inhibition was shown to be an effective approach to (re)
sensitize resistant AML cells to prior drugs. As expected, 
MCL-1 inhibition is able to reverse venetoclax or ABT-
737 resistance [107, 132, 133]. In addition, MCL-1 inhibi-
tion is capable to sensitize AML cells to multiple other 
drugs. Suppression of MCL-1 in FLT3-ITD AML cells 
significantly sensitized cells to cytarabine and daunoru-
bicin. More recent data also pointed to superior activ-
ity of BET protein inhibitors in combination with either 
BCL-2 or MCL-1 targeting BH3-mimetics [134]. Finally, 
the association between MCL-1 expression or depend-
ency and genetic events in AML patients offers excellent 
Table 1 Pharmacological characteristics of the main MCL‑1 inhibitors










BAK dependent activity Activity in solid tumors?
S63845 Ki < 1.2 nM Yes No Yes Yes Few: NSCLC, breast cancer, 
melanoma
AMG 176 Ki = 0.06 nM Yes No Yes Yes Breast cancer
AZD5991 Ki = 0.2 nM Yes No Yes Yes n/a
VU661013 Ki = 97 ± 30 pM n/a no -(not at protein level) n/a n/a
Compound 42 Ki = 0.03 nM n/a n/a Yes Probably (> 10-fold shift 
in IC50 in BAX/BAK KO 
cells)
TNBC, but lower activity as 
compared to hemato-
logical tumors  (promising 





Ki = 1.2–96.4 nM n/a n/a n/a Yes NSCLC
Table 2 Current clinical trials with MCL‑1 inhibitors
Compound Company Trial Nr Study Administration Indication
S64315 Servier NCT02979366 Phase I, monotherapy IV AML/MDS
S64315 Servier NCT03672695 Phase I, combination with venetoclax IV AML/MDS
MIK665 Novartis NCT02992483 Phase I, monotherapy IV MM/Lymphoma
ABBV-467 Abbvie NCT04178902 Phase I, monotherapy IV MM
AZD5991 Astra-Zenaca NCT03218683 Phase I, monotherapy and combina-
tion
IV Refractory Hematological malignancies
PRT1419 Prelude Therapeutics NCT04543305 Phase I, monotherapy Oral Refractory Hematological malignancies
AMG397 Amgen NCT03465540 Phase I, monotherapy Oral MM/AML/NHL
AMG176 Amgen NCT02675452 Phase I, Monotherapy IV MM/AML
AMG176 Amgen NCT03797261 Phase I, combination with venetoclax IV AML/Lymphoma
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strategies for precision medicine approaches. Besides 
FLT3-ITD, PTPN11 mutations are closely linked to 
MCL-1 upregulation, venetoclax resistance and meta-
bolic reprogramming toward increased oxidative phos-
phorylation and glycolysis. These tumor clones are 
highly sensitive to MCL-1 inhibition, which is linked to 
decreased oxidative phosphorylation, thus overcoming 
unmet medical needs in AML [135, 136].
Targeting of MCL‑1 with small molecule inhibitors
The poor selectivity and low affinity of the first inhibi-
tors and the reduced bioavailability of others (e.g., 
A-1210477) delayed the clinical development of potent 
MCL-1 inhibitors. Specific targeting of MCL-1 is par-
ticularly challenging due to its large, surface-exposed 
hydrophobic BH3 binding groove [137, 138]. Some of 
the putative MCL-1 inhibitors (Gossypol and its deriva-
tives), which demonstrated high efficacy in preclinical 
studies, showed various off-target effects not associated 
with the direct inhibition of MCL-1 (e.g., upregulation 
of NOXA) [139]. The indirect targeting of MCL-1 was 
also exploited as key mechanism of action of alternative 
drug classes such as CDK9 inhibitors or deubiquitination 
inhibitors [140, 141]. However, during the evolution of 
MCL-1 inhibitors, their affinities improved from micro-
molar to subnanomolar which finally enabled the design 
and synthesis of highly potent and specific clinical-grade 
MCL-1 inhibitors (Table 1). Up to date, three published 
compounds moved into clinical trials.
The first published compound of these pioneer-
ing activities was S63845  [109]. The lead compound for 
S63845 was derived from thienopyrimidine amino acids 
and further developed via an NMR-based fragment 
screen in combination with structure-guided drug design 
[142]. The compound binds to conserved Arg263 and 
the P2 plus P4 hydrophobic pockets of the MCL-1 BH3 
binding groove with a  KD of 0.19  nM and  Ki < 1.2  nM. 
Concurrent binding to either BCL-2 or BCL-xL was not 
observed  (Ki > 10 000 nM). As expected, S63845 displayed 
impressive potency at low nanomolar concentrations in 
preclinical in  vitro and in  vivo models of hematological 
malignancies, including MM, AML, CML and c-MYC-
driven Burkitt lymphoma. S63845 treatment (25  mg/
kg) led to a complete tumor regression at day 100 post-
treatment in xenograft models of MM and a 70% cure 
rate in immune-competent Eµ-MYC mouse lympho-
mas, respectively [109]. Concerns about potential dose-
limiting adverse events due to the six-fold lower affinity 
of S63845 for murine vs. human MCL-1 were retracted 
by recent data obtained in a humanized MCL-1 mouse 
model. S63845 treatment at the maximum tolerated dose 
of 12.5 mg per kg cured 60% of humanized Eµ-MYC lym-
phomas with only a transient reduction of B cells and 
red blood cells [143]. This underlines the presence of a 
therapeutic window which is currently evaluated with 
the S63845-related compound S64315/MIK665 in ongo-
ing clinical studies. The antitumor activity of S64315/
MIK665 was studied in different in  vitro and in  vivo 
models of hematological malignancies (AML, MM and 
DLBCL). In  vitro, a strong synergy was observed when 
S64315/MIK665 was combined with specific BCL-2 
inhibitors. This synergy was confirmed in  vivo where 
durable responses were seen in xenograft models [144].
Following the path of S63845, the highly potent and 
specific MCL-1 inhibitors AMG 176 and AZD5991 were 
disclosed in 2018 [107, 145]. AMG 176 represents the 
first-in-class orally bioavailable MCL-1 inhibitor. AMG 
176 was obtained using structure-guided drug design 
approaches and conformational restriction to optimize 
its properties  (Ki = 0.06 nM). On-target activity was veri-
fied in preclinical models and large cell line screenings 
(n = 952) revealed hematological malignancies (MM, 
AML, B-cell lymphoma, Burkitt lymphoma, ALL) as the 
indications of highest relevance. The potency of AMG 
176 was verified in MM xenograft models and an ortho-
topic model of AML at doses of 30 mg/kg and 60 mg/kg, 
respectively [107]. Similar to S63845, AMG 176’s affinity 
for murine MCL-1 is significantly reduced as compared 
to human MCL-1  (Ki = 0.044 µM). Thus, Caenepeel et al. 
likewise evaluated AMG 176 in a humanized MCL-1 
knock-in mouse model demonstrating dose-dependent 
decreases in B cells, monocytes and neutrophils. How-
ever, no overt systemic toxicity was observed at doses of 
30  mg/kg or 60  mg/kg and also the combination treat-
ment with venetoclax was well tolerated [107]. AMG 
397, derived from AMG 176, is more potent and has an 
improved pharmacokinetic profile [146]. Cell lines from 
hematologic malignancies including AML, multiple mye-
loma and DLBCL exhibited greatest sensitivity to AMG 
397 in a large tumor cell line profiling screen. Admin-
istration of AMG397 to MM or AML bearing mice 
resulted in significant tumor regressions and in synergis-
tic activity when combined with venetoclax [146].
AZD5991 is the fourth published MCL-1 inhibitor that 
is currently undergoing clinical testing. AZD5991 was 
obtained by optimization of previously reported indole-
2-carboxylic acids. Structure-guided design led to the 
synthesis of a highly potent and selective compound 
 (Ki = 0.2  nM) with no overt binding affinity for BCL-2 
or BCL-xL  (Ki = 6.8 and 18 µM, respectively). Similar to 
other MCL-1 inhibitors, AZD5991 demonstrated strong 
selectivity for hematological cancer cell lines, whereas 
only subsets of solid tumors were characterized as sen-
sitive (NSCLC, breast cancer). In MM xenograft mod-
els, AZD5991 at 100  mg per kg resulted in complete 
tumor regression. 88% tumor regression was noted at 
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sub-optimal concentrations (30 mg per kg) in combina-
tion with bortezomib. Accordingly, 71% of tested primary 
MM cells (n = 48) were found to be highly AZD5991 sen-
sitive (EC50 < 100 nM). Similar efficacy was observed in 
murine and rat AML models [145].
Several additional compounds that were reported to 
specifically target MCL-1 have been disclosed during the 
last two years. VU661013 was developed by the group of 
Stephen Fesik and possesses a remarkable target affinity 
 (Ki of 97 ± 30 pM) with no sign of cross-binding to BCL-2 
 (Ki = 0.73 µM) or BCL-xL  (Ki > 40 µM) [147]. VU661013 
demonstrated potent in vitro and in vivo activity in mod-
els of AML as well as patient-derived AML cells and 
xenograft models. Moreover, VU661013 showed strong 
synergy with venetoclax and its activity correlated with 
BH3 profiling which confirms the applicability of this 
assay for biomarker studies. Interestingly, residual AML 
cells isolated from VU661013 in  vivo studies displayed 
MCL-1 inhibitor resistance with a concurrent increase in 
the sensitivity to venetoclax [147]. Ongoing efforts in the 
Fesik lab recently led to the synthesis of compound 42. 
The development of this substance used structure-based 
design and several rounds of optimization starting from 
tricyclic diazepinones [148]. Compound 42 halted tumor 
growth and was well tolerated at doses up to 100 mg per 
kg in xenograft models of MM and TNBC. Although 
compound 42 activity was limited in the latter, strong 
synergism was observed in vivo in combination with doc-
etaxol or doxorubicin which is of great promise for the 
introduction of MCL-1 inhibitors outside the range of 
hematological malignancies.
In addition to the mentioned compounds, several alter-
native strategies are currently exploited to obtain novel 
clinical-grade MCL-1 inhibitors. For instance, b-car-
boline copper(II) complexes were described as MCL-1 
inhibitors that act in a BAX/BAK dependent manner 
and show potent anti-tumor activity in preclinical can-
cer models that was even superior as compared to the 
activity of AZD5991 (57% vs 23% tumor growth inhibi-
tion at 10 mg per kg in NCI-H460 tumor cell xenografts) 
[149]. These data can be used to build on for the further 
development of more potent and specific metal-based 
MCL-1 inhibitor structures. Also, proteolysis-targeting 
chimeras (PROTACs) represent a promising approach 
to target MCL-1. PROTACs are engineered bifunctional 
molecules composed of a target-binding ligand joined 
via a linker to an effector ligand that binds to E3 ubiqui-
tin ligase to trigger proteasomal degradation of the tar-
get protein [150]. In 2019, two MCL-1 PROTACs were 
reported. The first one linked a moiety of the MCL-1 
inhibitor A1210477 to 4-hydroxythalidomide, a thalido-
mide metabolite, that binds to the cereblon (CRBN) pole 
[151]. This PROTAC had a  KD of 30 nM with MCL-1 and 
directly degraded MCL-1 via the E3 ligase and cereblon-
directed proteasome–ubiquitin pathway. The second 
PROTAC combined another MCL-1 binding compound 
and the cereblon–ligand pomalidomide. This compound 
selectively induced a 70% decrease in MCL-1 levels of 
treated HELA cells lines at 1 μM and progressively down-
regulated it to less than 10% at 10 μM [152].
Taken together, different drug development strategies 
led to the recent development and clinical translation of 
potent MCL-1 inhibitors. These compounds are char-
acterized by their impressive potency, on-target activity 
(i.e., BAK dependent induction of apoptosis), a stabilizing 
effect on MCL-1 protein at least in non-sensitive cells, an 
inverse correlation between activity and BCL-xL expres-
sion levels as well as their preferential activity in hema-
tological malignancies. These characteristics are shared 
among the mentioned MCL-1 inhibitors, suggesting that 
they can be used to define this novel drug class. (Table 1) 
[147].
Clinical development
Soon after their disclosure, the first dose-finding studies 
were started by Servier/Vervalis, Amgen and Astra-Zen-
eca (cfr Table 2). Instead of S63845, S64315/MIK665 was 
used in monotherapy or in combination with venetoclax 
for phase I trials in AML/MDS and myeloma.
These first pioneering studies were restricted to hema-
tological malignances, which is not surprising given their 
dependence on MCL-1. Preliminary results on the first 
26 patients with relapsed MM, treated with increasing 
doses of AMG-176, were recently disclosed [153]. The 
maximum tolerable dose was not reached. The side-
effects were mostly hematological (neutropenia and 
anemia) and gastro-intestinal (nausea and diarrhea). An 
anti-tumor effect was seen in 11 patients with 1 complete 
remission, 2 partial responses and 8 patients with sta-
ble disease. A first alert concerning on-target/off-tumor 
toxicity came from the AMG-397 trial that was put on 
hold because of cardiac side effects. Because MCL-1 is 
implicated in normal cardiac myocyte functioning, these 
side effects are probably directly related to the on-target 
activity of these compounds and may limit the therapeu-
tic window of MCL-1 inhibitors.
In addition to the compounds described in the previ-
ous sections, two undisclosed compounds are being used 
in two recent studies. Abbvie, who has a long tradition 
in BCL-2 inhibiting compounds, is testing ABBV-467 
in monotherapy for multiple myeloma patients. Prel-
ude Therapeutics is starting a phase I clinical trial with 
an undisclosed MCL-1 inhibitor PRT1419. This com-
pound showed selective inhibition of MCL-1, and its oral 
administration to tumor-bearing mice resulted in tumor 
regression. This company patented two classes of MCL-1 
Page 14 of 19Bolomsky et al. J Hematol Oncol          (2020) 13:173 
Fig. 4 Heterogeneous BCL-2 family dependency profiles direct the application strategies for MCL-1 inhibitors in cancer. The prospects of MCL-1 
inhibitors are closely linked to the mitochondrial priming status of tumor cells. In principle, cancerous cells are primed for apoptosis as compared 
to healthy cells due to the, e.g., oncogene associated upregulation of the apoptosis machinery. This leads to a tight balance between pro-survival 
and pro-apoptotic proteins. Hematopoietic cancer cells are typically more primed than solid tumors due to the interconnectedness between age, 
tissue location and priming status (Sarosiek et al. 2017, Cancer Cell). Consequently, MCL-1 inhibitors have great potential as single-agent therapies 
in primed, strongly MCL-1-dependent cancers (left panel). In tumors with either moderate priming status (e.g., solid tumors) or primed, but 
MCL-1 co-dependent status, combination therapies are of maximal benefit (mid panel). In primed co-dependent cells, the addition of alternative 
BH3-mimetics (e.g., venetoclax) is a promising strategy. In solid tumors with moderate priming, chemotherapies can lead to the upregulation of 
pro-apoptotic BH3-only proteins (e.g., BIM) and thus prime tumor cells for apoptosis, which can be exploited by the addition of MCL-1 inhibitors. 
Finally, MCL-1 inhibitors are not effective in tumor cells with weak/no MCL-1 dependency (right panel). These cells can be either targeted by 
alternative BH3-mimetics (e.g., primed BCL-2 dependent cells) or alternative therapy classes to tackle apoptosis refractory cells. The latter are 
characterized by a loss of effector molecules (BAK, BAX), downregulation of pro-apoptotic BH3-only proteins (e.g., BIM) and/or the occurrence of 
inactivating mutations (e.g., BAK mutations). The precise targeting of apoptosis refractory cells therefore remains a major challenge irrespective of 
the availability of BH3-mimetics. This view on the application strategies of MCL-1 inhibitors is based on the work by Kristopher Sarosiek and Anthony 
Letai, recently reviewed by Singh et al. (Nat Rev Mol Cell Biol, 2019)
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inhibitors: one based on chemically modified esters of 
propionic acid (WO2020123994) and a second one based 
on spiro-sulfonamide derivatives (WO2020097577).
In spite of the drawback with AMG-397, the ongo-
ing clinical  exploration  of the  the additional com-
pounds  raises hope  that at least one of these molecules 
will present a favorable safety profile and clinical effi-
cacy. At that moment, one can imagine extrapolation 
toward solid tumors where these compounds could be 
combined with either chemotherapeutic treatments or 
targeted treatments. More stratified personalized treat-
ment approaches could be proposed based on BH3 pro-
filing to define the priming status of cancer cells as well as 
dependency toward one of the anti-apoptotic BCL-2 fam-
ily proteins [154]. BH3 profiling uses synthetic peptides, 
often derived from the BH3 domain of the pro-apoptotic 
BCL-2 family members, to dissect the functional rele-
vance of each BCL-2 family member in a cell’s apoptosis 
machinery [154, 155]. It should be stressed that conven-
tional mRNA expression is insufficient to predict the 
dependency on anti-apoptotic proteins or the response 
to specific inhibitors (as illustrated in Table 1). Functional 
assays (e.g., mitochondrial profiling or CRISPR/Cas9 
screens) are more adequate to study the implications of 
distinct BCL-2 family members for tumor cell survival. 
Combining this BH3 profiling with clinically active com-
pounds targeting MCL-1 or BCL-2 would thus open the 
door to biomarker-driven medicine (Fig. 4).
Conclusion
MCL-1 contributes to tumor cell survival by interfering 
with the apoptotic machinery. Previous studies showed 
that hematological malignancies are highly depend-
ent on MCL-1. Highly potent and specific inhibitors 
have been developed and entered into clinical trials for 
refractory hematological malignancies. The first results 
show some promising anti-tumor effects, but alerted 
also for potential cardiac toxicity. Combination of MCL-1 
inhibitors with other targeted treatments or chemother-
apeutic regimes will allow to overcome intrinsic apopto-
sis-resistance and to include them in biomarker-driven 
treatments. The latter should be based on functional 
assessments of BCL-2 family dependencies, because 
RNA or protein expression is not predictive for response 
to MCL-1-inhibitors. With the clinical development 
and success of the BCL-2 inhibitor venetoclax in mind, 
MCL-1 inhibitors may become the next novel class of 
anti-tumor agents with considerable potential across dif-
ferent malignancies.
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